Status:
COMPLETED
Cognitive Biases Under Ketamine
Lead Sponsor:
Centre Hospitalier St Anne
Collaborating Sponsors:
Fondation pour la Recherche Médicale
Fondation Fyssen
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-39 years
Phase:
NA
Brief Summary
Characterise cognitive biases resulting from low dose ketamine infusion, used as a pharmacological model of psychosis. Our assumption is that low dose ketamine results in reasoning biases by impairin...
Detailed Description
Ketamine is a non-competitive glutamate NMDA antagonist. The infusion of subanesthetic doses of ketamine results in sub-clinical schizophrenia-like positive symptoms in healthy controls. The safety of...
Eligibility Criteria
Inclusion
- Right-handed (as assessed by the Edinburgh scale)
- Aged 18 to 39
- Having given an informed consent
- Health insurance
Exclusion
- Pregnant or breastfeeding woman (a urine pregnancy test will be offered in doubt)
- Personal or first-degree family history of psychosis
- Personal history of mood disorder, anxiety disorder, obsessive-compulsive disorder, somatoform disorder, dependence on a psychoactive substance, behavior disorder incompatible with a 2 hours EEG recording.
- Psychotropic treatment, current or stopped for less than 1 month, including antidepressant, anxiolytic but excluding hypnotic treatments.
- Personal history of neurologic disorder in relation to the central nervous system : congenital malformation of the brain, brain tumor, multiple sclerosis, degenerative disease of the central nervous system, epilepsy, current or in remission for less than 3 years or still requiring a medical treatment, inflammatory disease of the central nervous system dating under a year or having resulted in sequelae.
- Known hypertension or blood pressure above 140/90 mmHg upon clinical examination, congenital heart disease, ischemic heart disease, cardiac insufficiency, supraventricular and ventricular heart rhythm disorder.
- Person with restricted liberty, as a result of judicial or administrative measures
- Persons under involuntary commitment as a result of a psychiatric disorder.
- Person subject to a measure of legal protection or unable to consent.
- Known intolerance ketamine.
Key Trial Info
Start Date :
September 8 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 29 2022
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT02235012
Start Date
September 8 2014
End Date
April 29 2022
Last Update
July 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Sainte Anne
Paris, France, 75014